Zambon’s Hopledo wins CHMP backing, but can fewer daily doses reshape Parkinson’s care?
See how Zambon’s Hopledo could change Parkinson’s motor fluctuation care in Europe after a positive CHMP opinion, and what risks remain.
Pharma & Biotech